U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07142226) titled 'Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC' on Aug. 18.
Brief Summary: Biliary tract cancer (BTC) is a rare and heterogeneous disease with high incidence and mortality in Korea. Molecular profiling has enabled the identification of actionable alterations such as Isocitrate Dehydrogenase 1 (IDH1) mutations, FGFR2 fusions, ERBB2 amplifications, and dMMR/MSI-H status. However, the utility of tumor tissue-based next-generation sequencing (NGS) is often limited by difficulties in obtaining adequate tissue samples and the lack of in-house sequencing capacity across many hospitals.
Circulating tumor DNA (ctDNA) analysi...